Volume 5, Issue 5-6

2018pp 120—208

About the Cover

The cover for this issue of Oncoscience features Figure 1 ("A new concept in NF2 pharmacotherapy: targeting fatty acid synthesis") from Stepanova et al.

Editorials

Targeting MYC for triple-negative breast cancer treatment

Nancy Klauber-DeMore, Bradley A. Schulte, Gavin Y. Wang

https://doi.org/10.18632/oncoscience.414pp 120—121

PDF Full-Text

BETter together: exploiting BRD4-functions in transcription to inform rational combinations

Fabio Savarese, Norbert Kraut

https://doi.org/10.18632/oncoscience.415pp 122—123

PDF Full-Text

Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer

Laetitia Seguin, Chloé Féral

https://doi.org/10.18632/oncoscience.416pp 124—125

PDF Full-Text

A new concept in NF2 pharmacotherapy: targeting fatty acid synthesis

Dina S. Stepanova, Lanita Braun, Jonathan Chernoff

https://doi.org/10.18632/oncoscience.417pp 126—127

PDF Full-Text

The pro-tumoral function of HACE1

Najla El-Hachem, Robert Ballotti

https://doi.org/10.18632/oncoscience.418pp 128—129

PDF Full-Text

Poldip2 takes a central role in metabolic reprograming

Felipe Paredes, Izabela Suster, Alejandra San Martin

https://doi.org/10.18632/oncoscience.419pp 130—131

PDF Full-Text

Curing cancer? Further along the new pH-centric road and paradigm

S. Harguindey, T. Koltai, S. J. Reshkin

https://doi.org/10.18632/oncoscience.422pp 132—133

PDF Full-Text

Combating resistance to DNA damaging agents

Jung-Suk Choi, Anthony Berdis

https://doi.org/10.18632/oncoscience.423pp 134—136

PDF Full-Text

Leveraging MYC as a therapeutic treatment option for TNBC

Jason P.W. Carey, Khandan Keyomarsi

https://doi.org/10.18632/oncoscience.424pp 137—139

PDF Full-Text

Advances in biomarkers and treatment strategies for HPV-associated head and neck cancer

Cassie Pan, Wendell G. Yarbrough, Natalia Issaeva

https://doi.org/10.18632/oncoscience.425pp 140—141

PDF Full-Text

Metastasis-associated upregulation of ER-Golgi trafficking kinetics: regulation of cancer progression via the Golgi apparatus

Breege V. Howley, Philip H. Howe

https://doi.org/10.18632/oncoscience.426pp 142—143

PDF Full-Text

Targeting p27 tyrosine phosphorylation as a modality to inhibit CDK4 and CDK2 and cause cell cycle arrest in breast cancer cells

Stacy W. Blain

https://doi.org/10.18632/oncoscience.427pp 144—145

PDF Full-Text

Adipocyte metabolism of the chemotherapy daunorubicin

Steven D. Mittelman, Etan Orgel

https://doi.org/10.18632/oncoscience.428pp 146—147

PDF Full-Text

NEO212: sub-cytotoxic doses capable of inhibiting glioma stem cell invasion

Nagore I. Marín-Ramos, Florence M. Hofman, Thomas C. Chen

https://doi.org/10.18632/oncoscience.429pp 148—149

PDF Full-Text

VEGF-mTOR signaling links obesity and endometrial cancer

Subhransu S. Sahoo, Pradeep S. Tanwar

https://doi.org/10.18632/oncoscience.430pp 150—151

PDF Full-Text

Targeting Cdk5 for killing of breast cancer cells via perturbation of redox homeostasis

Saranya NavaneethaKrishnan, Jesusa L. Rosales, Ki-Young Lee

https://doi.org/10.18632/oncoscience.431pp 152—154

PDF Full-Text

An oncogenic role for microRNA-146b in the thyroid

Julia Ramírez-Moya, Pilar Santisteban

https://doi.org/10.18632/oncoscience.432pp 155—156

PDF Full-Text

GPR50 in TGFβ signaling and breast cancer

Raise Ahmad, Stefanie Wojciech, Ralf Jockers

https://doi.org/10.18632/oncoscience.433pp 157—158

PDF Full-Text

KDM2B in papillomavirus-related cancer

Elektra Peta, Giulia Masi, Luisa Barzon

https://doi.org/10.18632/oncoscience.434pp 159—160

PDF Full-Text

Quantitative pharmacology in antibody-drug conjugate development: armed antibodies or targeted small molecules?

Ian Nessler, Eshita Khera, Greg M. Thurber

https://doi.org/10.18632/oncoscience.435pp 161—163

PDF Full-Text

HDL and the golden key to cancer immunity?

Michael P. Plebanek, Debayan Bhaumik, C. Shad Thaxton

https://doi.org/10.18632/oncoscience.436pp 164—166

PDF Full-Text

The systemic control of cancers by the osteoblasts

Claire-Sophie Devignes, Yetki Aslan, Sylvain Provot

https://doi.org/10.18632/oncoscience.437pp 167—168

PDF Full-Text

Using interferon-beta to combat cancer stem cell properties in triple negative breast cancer

Mary R. Doherty, Mark W. Jackson

https://doi.org/10.18632/oncoscience.438pp 169—171

PDF Full-Text

The BBN model: a mouse bladder cancer model featuring basalsubtype gene expression and MLL3/MLL4 genetic disruption

Damiano Fantini, Joshua J. Meeks

https://doi.org/10.18632/oncoscience.439pp 172—173

PDF Full-Text

Efferocytosis and prostate cancer skeletal metastasis: implications for intervention

Hernan Roca, Laurie K. McCauley

https://doi.org/10.18632/oncoscience.440pp 174—176

PDF Full-Text

A mechanism for cell non-autonomous inactivation of the tumor suppressor DAB2IP

Arianna Bellazzo, Licio Collavin

https://doi.org/10.18632/oncoscience.441pp 177—178

PDF Full-Text

Macrophages as prognostic biomarkers in human melanoma

Rafael Samaniego, Alba Gutiérrez-Seijo, Paloma Sánchez-Mateos

https://doi.org/10.18632/oncoscience.442pp 179—180

PDF Full-Text

Reviews

Exosomes: mediators of bone diseases, protection, and therapeutics potential

Jyotirmaya Behera, Neetu Tyagi

https://doi.org/10.18632/oncoscience.421pp 181—195

View Abstract PDF Full-Text

Research Papers

The therapeutic properties of resminostat for hepatocellular carcinoma

Jun Zhao, Steven G. Gray, Martin Wabitsch, Catherine M. Greene, Matthew W. Lawless

https://doi.org/10.18632/oncoscience.420pp 196—208

View Abstract PDF Full-Text